Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL793322 | 0.97 | CA12 (0.36) | CA12CA2CA9HDAC1HDAC2 | |
| SCHEMBL11330893 | 0.86 | CA12 (0.42) | CA12CA2CA9HDAC1HDAC2 | |
| SCHEMBL11342485 | 0.79 | CA12 (0.37) | CA12CA2CA9CHRM1CHRM3 | |
| SCHEMBL28755351 | 0.78 | CA12 (0.33) | CA12CA2CA9MAPK1TSHR | |
| SCHEMBL2465652 | 0.78 | — | — | |
| SCHEMBL5631353 | 0.77 | CA12 (0.36) | CA12CA2CA9MAPK1TSHR | |
| Hydrochloric Acid SCHEMBL10752958 | 0.75 | CA12 (0.34) | CA12CA2CA9MAPK1TSHR | |
| Hydrochloric Acid SCHEMBL10752962 | 0.75 | CA12 (0.34) | CA12CA2CA9MAPK1TSHR | |
| SCHEMBL3900071 | 0.75 | ALDH1A1 (0.39) | TSHRALDH1A1PHF8KDM2A | |
| SCHEMBL11220511 | 0.73 | CA12 (0.38) | CA12CA2CA9MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774722-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | Epiodyne, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019195634-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| EP-2961736-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2016-01-06 | — | — | EP | disclosed |
| WO-2015057847-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| EP-2817345-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | Cerulean Pharma Inc. (US) | 2014-12-31 | — | — | EP | disclosed |
| WO-2014131777-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2014-09-04 | — | — | WO | disclosed |
| US-20140037573-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2013126564-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2013-08-29 | — | — | WO | disclosed |
| EP-2616443-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| EP-1383737-A1 | PROCESS FOR THE PREPARATION OF ALKYL-N-(3-DIMETHYLAMINO)ALKYLCARBAMATES | Bayer CropScience GmbH (DE) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002090322-A1 | PROCESS FOR THE PREPARATION OF ALKYL-N-(3-DIMETHYLAMINO)ALKYLCARBAMATES | BAYER CROPSCIENCE GMBH (DE) | 2002-11-14 | — | — | WO | disclosed |
| EP-1095940-A2 | Derivatives of 9-(3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphto[2,3-d][1,3]dioxol-6(5aH)-one, method for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140037573-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | SYNCRIP, EXOSC5, EXOSC9 | CA12 657/4885CA2 4050/4885CA9 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.